News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Dec 02, 2019~ Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~
DEER PARK, Ill., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 26, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been invited to present at the following two investor conferences in December: 8th Annual Benchmark...
- Nov 21, 2019Board Realignment Follows SWK's Acquisition of Enteris BioPharma
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, announced today that Winston Black, Chief Executive Officer of SWK, has been named...
- Nov 18, 2019
Corporate Highlights Acquired Enteris BioPharma, Inc. ("Enteris") a biotechnology company offering innovative formulation solutions utilizing its proprietary oral drug delivery technology,...
- Nov 15, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 15, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Nov 15, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced it appointed Michael DiTolla, DDS, FAGD to its board of directors, effective November 14, 2019. The appointment...
- Nov 14, 2019Biorphen® Expected to Launch by End of November
DEER PARK, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 13, 2019
DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Nov 08, 2019Eyes global delivery of Modular Immune Profile (MIP) Assay for Autoimmune Disease
LOS ANGELES, CA – November 8, 2019 – DxTerity Diagnostics Inc. has announced the signing of a multi-year licensing and supply agreement with Thermo Fisher Scientific. Under the terms of the...
- Nov 08, 2019Along with the release of new Longitudinal SLE Clinical Study Results, the diagnostics company announces the commercial launch of DxTerity Type 1 Interferon Testing
LOS ANGELES, CA – November 8, 2019 – DxTerity® Diagnostics Inc. has announced the results of a longitudinal clinical study with the Oklahoma Medical Research Foundation (OMRF) demonstrating...